A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.

Ester ConversanoHanna DebiecManuela ColucciFrancesco EmmaPierre RoncoMarina Vivarelli

Published in: Pediatric nephrology (Berlin, Germany) (2023)

Obinutuzumab was safe and well-tolerated, and may therefore represent an effective therapeutic alternative in children with primary MN and rituximab resistance.

Keyphrases

chronic lymphocytic leukemia
diffuse large b cell lymphoma
young adults
hodgkin lymphoma
mental health
ionic liquid